DUKX yields 2.41% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, DUKX + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DUKX + PFE for your $10,000?
DUKX invests in unaffiliated global ex-US equity ETFs using a proprietary trend-following strategy. The underlying ETFs, either passively managed or actively managed, may invest in developed market ex-US and emerging market equities of any market cap. The fund expects to allocate nearly all its assets to these ETFs. In selecting investments, the adviser determines buy and sell signals by calculating the upper and lower bands of the short-term exponential moving averages. A buy signal is initiated when a potential uptrend in a candidate ETF is detected. To limit drawdowns of the overall fund, an ETF is sold when a sell signal is identified. Upon selling a position, the fund may reinvest in another ETF or temporarily hold cash equivalents, including US T-bills, money market funds, and investment-grade short-term bond ETFs. The fund is not limited by any constraints on the number or type of underlying ETFs. The adviser periodically reviews and adjusts the allocation of the fund.
Full DUKX Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.